Trevi Therapeutics Inc (TRVI)
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company listed on NASDAQ under the symbol TRVI. The company is focused on developing and commercializing therapies for chronic cough, including cough associated with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, as well as refractory chronic cough. Its lead product candidate, Haduvio, is an oral extended-release formulation of nalbuphine that is being studied in a phase 2b clinical trial for chronic cough in IPF and in a phase 2a study for refractory chronic cough. Trevi also has a license agreement with Keenova Therapeutics plc covering products based on nalbuphine hydrochloride in different formulations. Founded in 2011, the company is headquartered in New Haven, Connecticut.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TRVI
|
$9.16
|
-48.1% Downside
|
Overvalued
|
$26.18
|
48.5% Upside
|
Undervalued
|
Good
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-55.1x
|
14.6x
|
—
|
2.381 B
|
2.343 B
|
0.0%
|
83.7%
|
188.5
|
—
|
99.6%
|
